Nitrogen-containing bisphosphonates inhibit RANKL- and M-CSF-induced osteoclast formation through the inhibition of ERK1/2 and Akt activation

Journal of Biomedical Science

Volumn 21, Issue 1, 2014, Pages

  Tsubaki, Masanobu ^a   Komai, Makiko ^a   Itoh, Tatsuki ^b   Imano, Motohiro ^b   Sakamoto, Kotaro ^a   Shimaoka, Hirotaka ^a   Takeda, Tomoya ^a   Ogawa, Naoki ^a,c   Mashimo, Kenji ^a,d   Fujiwara, Daiichiro ^a,d   Mukai, Junji ^c   Sakaguchi, Katsuhiko ^d   Satou, Takao ^b   Nishida, Shozo ^a  

^a KINKI UNIVERSITY   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Izumi Municipal Hospital   (Japan)

^d JAPANESE RED CROSS WAKAYAMA MEDICAL CENTER   (Japan)

Author keywords

Geranylgeranyl pyrophosphate; MEK1 2; Nitrogen containing bisphosphonate; PI3K

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALENDRONIC ACID; CATHEPSIN K; COLONY STIMULATING FACTOR 1; GERANYLGERANYL PYROPHOSPHATE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MEVALONIC ACID; MINODRONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN KINASE B; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; ISOPRENOID PHOSPHATE; NITROGEN; ONCOPROTEIN;

ANIMAL CELL; ARTICLE; CELL FUSION; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MOUSE; NONHUMAN; OSTEOCLASTOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; ANIMAL; APOPTOSIS; BIOSYNTHESIS; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; MACROPHAGE; METABOLIC BONE DISEASE; METABOLISM; OSTEOCLAST; PATHOLOGY; SIGNAL TRANSDUCTION;

ORYCTOLAGUS CUNICULUS;

ALENDRONATE; ANIMALS; APOPTOSIS; BONE DISEASES, METABOLIC; DIPHOSPHONATES; HUMANS; IMIDAZOLES; MACROPHAGE COLONY-STIMULATING FACTOR; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; NITROGEN; ONCOGENE PROTEIN V-AKT; OSTEOCLASTS; POLYISOPRENYL PHOSPHATES; RANK LIGAND;

EID: 84893171202     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-21-10     Document Type: Article

References (40)

1. Advances in bone biology: the osteoclast. Roodman GD, Endocr Rev 1996 17 308 332 8854048
2. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ, Endocr Rev 1999 20 345 357 10.1210/edrv.20.3.0367 10368775
3. Bone resorption by osteoclasts. Teitelbaum SL, Science 2000 289 1504 1508 10.1126/science.289.5484.1504 10968780
4. Reaching a genetic and molecular understanding of skeletal development. Karsenty G, Wagner EF, Dev Cell 2002 2 389 406 10.1016/S1534-5807(02)00157-0 11970890
5. Osteoclast differentiation and activation. Boyle WJ, Simonet WS, Lacey DL, Nature 2003 423 337 342 10.1038/nature01658 12748652
6. Genetic regulation of osteoclast development and function. Teitelbaum SL, Ross FP, Nat Rev Genet 2003 4 638 649 10.1038/nrg1122 12897775
7. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Lerner UH, Crit Rev Oral Biol Med 2004 15 64 81 10.1177/ 154411130401500202 15059943
8. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H, Sudo T, Shultz LD, Nishikawa S, Nature 1990 345 442 443 10.1038/345442a0 2188141
9. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM, Nature 1999 397 315 323 10.1038/16852 9950424
10. Mechanistic insight into osteoclast differentiation in osteoimmunology. Takayanagi H, J Mol Med 2005 83 170 179 10.1007/s00109-004-0612-6 15776286
11. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects. Dai XM, Ryan GR, Hapel AJ, Dominguez MG, Russell RG, Kapp S, Sylvestre V, Stanley ER, Blood 2002 99 111 120 10.1182/blood.V99.1.111 11756160
12. Cellular and molecular mechanisms of action of bisphosphonates. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC, Cancer 2000 88 2961 2978 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0. CO;2-L 10898340
13. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Keller RK, Fliesler SJ, Biochem Biophys Res Commun 1999 266 560 563 10.1006/bbrc.1999.1849 10600541
14. A new bisphosphonate, YM529 induces apoptosis in HL60 cells by decreasing phosphorylation of single survival signal ERK. Nishida S, Fujii Y, Yoshioka S, Kikuichi S, Tsubaki M, Irimajiri K, Life Sci 2003 73 2655 2664 10.1016/S0024-3205(03)00664-7 13679234
15. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits macrophage inflammatory protein 1 alpha expression and secretion in mouse myeloma cells. Tsubaki M, Kato C, Nishinobo M, Ogaki M, Satou T, Ito T, Kusunoki T, Fujiwara K, Yamazoe Y, Nishida S, Cancer Sci 2008 99 152 158 17979996
16. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2. Nishida S, Tsubaki M, Hoshino M, Namimatsu A, Uji H, Yoshioka S, Tanimori Y, Yanae M, Iwaki M, Irimajiri K, Biochem Biophys Res Commun 2005 328 91 97 10.1016/j.bbrc.2004.12.145 15670755
17. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA, Proc Natl Acad Sci USA 1999 96 133 138 10.1073/pnas.96.1.133 9874784
18. Biochemical and molecular mechanisms of action of bisphosphonates. Rogers MJ, Crockett JC, Coxon FP, Mönkkönen J, Bone 2011 49 34 41 10.1016/j.bone.2010.11.008 21111853
19. Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Miyamoto A, Kunisada T, Hemmi H, Yamane T, Yasuda H, Miyake K, Yamazaki H, Hayashi SI, Biochem Biophys Res Commun 1998 242 703 709 10.1006/bbrc.1997.8046 9464281
20. Macrophage inflammatory protein-1α induces osteoclast formation by activation of the MEK/ERK/c-Fos pathway and inhibition of the p38MAPK/IRF-3/IFN-β pathway. Tsubaki M, Kato C, Isono A, Kaneko J, Isozaki M, Satou T, Itoh T, Kidera Y, Tanimori Y, Yanae M, Nishida S, J Cell Biochem 2010 111 1661 1672 10.1002/jcb.22907 21053363
21. Bisphosphonates: from the laboratory to the clinic and back again. Russell RG, Rogers MJ, Bone 1999 25 97 106 10.1016/S8756-3282(99)00116-7 10423031
22. Nitrogen-containing bisphosphonate, YM529/ONO-5920, inhibits tumor metastasis in mouse melanoma through suppression of the Rho/ROCK pathway. Tanimori Y, Tsubaki M, Yamazoe Y, Satou T, Itoh T, Kidera Y, Yanae M, Yamamoto C, Kaneko J, Nishida S, Clin Exp Metastasis 2010 27 529 538 10.1007/s10585-010- 9342-z 20632074
23. Reduction of metastasis, cell invasion, and adhesion in mouse osteosarcoma by YM529/ONO-5920-induced blockade of the Ras/MEK/ERK and Ras/PI3K/Akt pathway. Tsubaki M, Satou T, Itoh T, Imano M, Ogaki M, Yanae M, Nishida S, Toxicol Appl Pharmacol 2012 259 402 410 10.1016/j.taap.2012.01.024 22326785
24. Bisphosphonate- and statin-induced enhancement of OPG expression and inhibition of CD9, M-CSF, and RANKL expressions via inhibition of the Ras/MEK/ERK pathway and activation of p38MAPK in mouse bone marrow stromal cell line ST2. Tsubaki M, Satou T, Itoh T, Imano M, Yanae M, Kato C, Takagoshi R, Komai M, Nishida S, Mol Cell Endocrinol 2012 361 219 231 10.1016/j.mce.2012.05. 002 22579611
25. Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway. Tsubaki M, Itoh T, Satou T, Imano M, Komai M, Ogawa N, Mukai J, Nishida S, Biochem Pharmacol 2013 85 163 172 10.1016/j.bcp.2012.10.009 23085435
26. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. Coxon FP, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ, J Bone Miner Res 2000 15 1467 1476 10.1359/jbmr.2000.15.8.1467 10934645
27. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Lee ZH, Kim HH, Biochem Biophys Res Commun 2003 305 211 214 10.1016/S0006-291X(03)00695-8 12745060
28. c-Fms and the alphavbeta3 integrin collaborate during osteoclast differentiation. Faccio R, Takeshita S, Zallone A, Ross FP, Teitelbaum SL, J Clin Invest 2003 111 749 758 10.1172/JCI200316924 12618529
29. Zoledronic acid inhibits RANK expression and migration of osteoclast precursors during osteoclastogenesis. Kimachi K, Kajiya H, Nakayama S, Ikebe T, Okabe K, Naunyn Schmiedebergs Arch Pharmacol 2011 383 297 308 10.1007/s00210-010-0596-4 21225243
30. Effects of bisphosphonates on osteoclastogenesis in RAW264.7 cells. Abe K, Yoshimura Y, Deyama Y, Kikuiri T, Hasegawa T, Tei K, Shinoda H, Suzuki K, Kitagawa Y, Int J Mol Med 2012 29 1007 1015 22447156
31. Bone metastasis: pathogenesis and therapeutic implications. Clezardin P, Teti A, Clin Exp Metastasis 2007 24 599 608 10.1007/s10585-007-9112-8 18008175
32. Pathophysiology of myeloma bone disease. Esteve FR, Roodman GD, Best Pract Res Clin Haematol 2007 20 613 624 10.1016/j.beha.2007.08.003 18070709
33. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Boissier S, Ferreras M, Peyruchaud O, Magnetto S, Ebetino FH, Colombel M, Delmas P, Delaissé JM, Clézardin P, Cancer Res 2000 60 2949 2954 10850442
34. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Clézardin P, Ebetino FH, Fournier PG, Cancer Res 2005 65 4971 4974 10.1158/0008-5472.CAN-05-0264 15958534
35. The bisphosphonate YM529 inhibits osteolytic and osteoblastic changes and CXCR-4-induced invasion in prostate cancer. Miwa S, Mizokami A, Keller ET, Taichman R, Zhang J, Namiki M, Cancer Res 2005 65 8818 8825 10.1158/0008-5472. CAN-05-0540 16204052
36. Effect of YM529 on a model of mandibular invasion by oral squamous cell carcinoma in mice. Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahala T, Clin Cancer Res 2005 11 2713 2719 10.1158/1078-0432.CCR-04-1767 15814653
37. The bisphosphonate YM529 inhibits osteoblastic bone tumor proliferation of prostate cancer. Yonou H, Ochiai A, Ashimine S, Maeda H, Horiguchi Y, Yoshioka K, Ogawa Y, Hatano T, Tachibana M, Prostate 2007 67 999 1009 10.1002/pros.20592 17440967
38. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Zhang H, Yano S, Miki T, Goto H, Kanematsu T, Muguruma H, Uehara H, Sone S, Clin Exp Metastasis 2003 20 153 159 10.1023/A:1022621622063 12705636
39. Bone cancer pain: the effects of the bisphosphonate alendronate on pain, skeletal remodeling, tumor growth and tumor necrosis. Sevcik MA, Luger NM, Mach DB, Sabino MA, Peters CM, Ghilardi JR, Schwei MJ, Röhrich H, De Felipe C, Kuskowski MA, Mantyh PW, Pain 2004 111 169 180 10.1016/j.pain.2004.06.015 15327821
40. Bisphosphonates and RANK ligand inhibitors for the treatment and prevention of metastatic bone disease. Neville-Webbe HL, Coleman RE, Eur J Cancer 2010 46 1211 1222 10.1016/j.ejca.2010.02.041 20347292